M. Temesvári

Is CYP2D6 phenotype predictable from CYP2D6 genotype

K. Monostory, K. Tóth, G. Hirka, 2018 .

Drug Interaction Potential of 2-((3,4-Dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the Novel Nonstatin-Type Cholesterol-Lowering Agent

J. Pascussi, Jure Acimovic, K. Monostory, 2009, Drug Metabolism and Disposition.

Estimation of Drug-Metabolizing Capacity by Cytochrome P450 Genotyping and Expression

K. Monostory, A. Belic, L. Kóbori, 2012, Journal of Pharmacology and Experimental Therapeutics.

High-resolution melting curve analysis to establish CYP2C19∗2 single nucleotide polymorphism: Comparison with hydrolysis SNP analysis.

K. Monostory, L. Kóbori, M. Temesvári, 2011, Molecular and cellular probes.

In response: Commentary on clinical significance of CYP2C9‐status‐guided valproic acid therapy in children

M. Garami, K. Monostory, K. Tóth, 2016, Epilepsia.

Clinical significance of CYP2C9‐status guided valproic acid therapy in children

M. Garami, K. Monostory, K. Tóth, 2015, Epilepsia.

Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A‐status in liver transplant recipients

K. Monostory, Z. Gerlei, L. Kóbori, 2020, British journal of clinical pharmacology.